Journal of Critical Care
Volume 24, Issue 1 , Pages 5-10 , March 2009

Physiology and biology of neuromuscular transmission in health and disease

References 

  1. Jonsson M, Wyon N, Lindahl SGE, et al. Neuromuscular blocking agents block carotid body neuronal nicotinic acetylcholine receptors. Eur J Pharmacol. 2004;497:173–180
  2. Jooste E, Zhang Y, Emala CW. Neuromuscular blocking agents' differential bronchoconstrictive potential in guinea pig airways. Anesthesiology. 2007;106:762–763
  3. Vizi ES, Lendvai B. Side effects of nondepolarizing muscle relaxants: relationship to their antinicotinic and antimuscarinic actions. Pharmacol Ther. 1997;73:75–89
  4. Cohen-Cory S. The developing synapse: construction and modulation of synaptic structures and circuits. Science. 2002;298:770–776
  5. Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a post-synaptic apparatus. Nat Rev Neurosci. 2001;2:791–805
  6. Fraterman S, Khurana TS, Rubinstein NA. Identification of acetylcholine receptor subunits differentially expressed in singly and multiply innervated fibers of extraocular muscles. Invest Ophthalmol Vis Sci. 2006;47:3828
  7. Betz WJ, Caldwell JH, Kinnamon SC. Increased sodium conductance in the synaptic region of rate skeletal muscle fibres. J Physiol (London). 1984;352:189–202
  8. Rich MM. The control of neuromuscular transmission in health and disease. Neuroscientist. 2006;12:134–142
  9. Engel AG. The therapy of congenital myasthenia syndromes. Neurotherapeutics. 2007;4:252
  10. Wang X, Engisch KL, Li Y, et al. Decreased synaptic activity shifts the calcium dependence of release at the mammalian neuromuscular junction in vivo. J Neurosci. 2004;24:10687–10692
  11. Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol. 2003;4:207
  12. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27:552–558
  13. Schurch B. The role of botulinum toxin in neurourology. Drugs Today (Barc). 2004;40:205
  14. Lowe NJ. Overview of botulinum neurotoxins. J Cosmet Laser Ther. 2007;9(Suppl 1):11–16
  15. Frick CG, Richtsfeld M, Martyn JAJ, et al. Long-term effects of botulinum toxin on neuromuscular function. Anesthesiology. 2007;106:1139–1146
  16. Lange DJ, Rubin M, Gelb DJ, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve. 1991;14:672–675
  17. Sieburth D, Ch'ng Q, Kaplan JM, et al. Systematic analysis of genes required for synapse structure and function. Nature. 2005;436:510–517
  18. Bigalke H, Rummel A. Medical aspects of toxin weapons. Toxicology. 2005;214:210–220
  19. Baker DJ. Critical care requirements after mass toxic agent release. Crit Care Med. 2005;33:S64–S74
  20. Martyn JAJ, Fukushima Y, Yang HS, et al. Muscle relaxants in burns, trauma, and critical illness. Int Anesthesiol Clin. 2006;44:123–143
  21. Martyn JAJ, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104:158–169
  22. Song Y, Panzer JA, Balice-Gordon RJ, et al. Formation and plasticity of neuromuscular synaptic connections. Int Anesthesiol Clin. 2006;44:145–178
  23. Martyn JAJ, White DA, Gronert GA, et al. Up- and down-regulation of skeletal muscle acetylcholine receptors. Anesthesiology. 1992;26:872
  24. Tsuneki H, Salas R, Dani JA. Mouse muscle denervation increases expression of alpha 7 nicotinic receptor with unusual pharmacology. J Physiol. 2003;547:169–179
  25. Wang H, Yu M, Tracey KJ, et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature. 2003;421:384–388
  26. Taylor P. Anticholinesterase agents. In:  Bruton LL,  Lazo JS,  Parker KL editor. Goodman & Gilman's pharmacological basis of therapeutics. 11th Ed.. New York, NY: McGraw-Hill Professional; 2006;p. 201
  27. Richtsfeld M, Blobner M, Martyn JAJ. Chronic administration of pyridostigmine leads to a myasthenia-like with down-regulation of acetylcholine receptors. In: Young Investigator Award for abstract to be presented at ASCCA at the ASA Annual Meeting, San Francisco, CA, October. 2003;
  28. de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107:239

☆ This study was supported in part by grants from the National Institute of General Medical Services (GM31569-25, GM21500-32 Project IV and GM 55082-10), Bethesda, Md, and from the Shriners Hospital Philanthropy, Tampa, FL (grants 8740, 8891, 8670, and 8530) to JAJM.

PII: S0883-9441(08)00178-0

doi: 10.1016/j.jcrc.2008.08.002

Journal of Critical Care
Volume 24, Issue 1 , Pages 5-10 , March 2009

Article Tools

* Image Usage & Resolution